Indaptus Therapeutics (INDP) is trading at $3.18 (6% up) in pre-market. The positive movement follows the company's recent announcement of a $12 million Regulation S private placement of 20 million common shares at $0.60 per share to non-U.S. accredited investors.
- The private placement, disclosed on June 24, 2026, aims to secure additional capital, a critical need for the company which previously warned of substantial doubt about its ability to continue as a going concern.
- Investor focus remains on the company's financing and strategic options as it navigates operational adjustments and pipeline evaluations.